India, May 2 -- Maiva Pharma, headquartered in Bengaluru and known as India's second-largest injectables Contract Development and Manufacturing Organization (CDMO) for North America, has announced a significant milestone in its growth journey.

The company has successfully raised approximately Rs 1,000 crore in primary and secondary funding from a fund managed by Morgan Stanley Private Equity Asia and India Life Sciences Fund - IV (ILSF - IV). This investment marks Maiva's first private equity fundraise and signals a significant move in the healthcare investment landscape.

The funding has been utilised to acquire a controlling stake from existing investors and to infuse primary capital into the company. Maiva Pharma plans to allocate the...